[18F]FDG-PET of giant-cell aortitis [5]

Rheumatology

Volumn 44, Issue 5, 2005, Pages 690-691

  Walter, M A ^a   Melzer, R A ^a   Graf, M ^b   Tyndall, A ^a   Muller Brand J ^a   Nitzsche, E U ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Institute of Clinical Pathology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL PAIN; AGED; AORTITIS; APPETITE DISORDER; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; GASTROSCOPY; GIANT CELL ARTERITIS; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LETTER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VOMITING; WEIGHT REDUCTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METHODOLOGY; SCINTISCANNING; TEMPORAL ARTERITIS;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; RADIOPHARMACEUTICALS; TEMPORAL ARTERITIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 21244453169     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh551     Document Type: Letter

References (1)

1. Webb M, Chambers A, Al-Nahhas A et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004;31:627-34